Skip to main content

Table 1 Baseline characteristics of the included patients

From: Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature

Variables Primary cohort Validation cohort P value
No. (%) No. (%)
No. of patients 911 456  
Age (years) 58 (48, 66) 57 (48, 67) 0.862
 T stage 0.699
 T1 248 (27.2) 125 (27.4)  
 T2 529 (58.1) 254 (55.7)  
 T3 110 (12.1) 65 (14.3)  
 T4 24 (2.6) 12 (2.6)  
N stage 0.266
 N0 435 (47.8) 224 (49.1)  
 N1 306 (33.6) 150 (32.9)  
 N2 95 (10.4) 48 (10.5)  
 N3 65 (7.1) 34 (7.5)  
 Nx 10 (1.1) 0 (0)  
TNM stage 0.878
 I 161 (17.7) 82 (18.0)  
 II 527 (57.8) 261 (57.2)  
 III 206 (22.6) 107 (23.5)  
 Unknown 17 (1.9) 6 (1.3)  
ER status 0.723
 Negative 192 (21.1) 90 (19.7)  
 Positive 682 (74.8) 350 (76.8)  
 Unknown 37 (4.1) 16 (3.5)  
PR status 0.920
 Negative 275 (30.2) 137 (30.0)  
 Positive 598 (65.6) 302 (66.2)  
 Unknown 38 (4.2) 17 (3.7)  
HER2 status 0.265
 Negative 653 (71.7) 340 (74.6)  
 Positive 155 (17.0) 62 (13.6)  
 Unknown 103 (11.3) 54 (11.8)  
Molecular subtype 0.495
 HR+/HER2- 523 (57.4) 277 (60.7)  
 HR+/HER2 +  124 (13.6) 52 (11.4)  
 HR−/HER2+ 31 (3.4) 10 (2.2)  
 TNBC 129 (14.2) 62 (13.6)  
 Unknown 104 (11.4) 55 (12.1)  
  1. TNM tumor-node-metastasis, ER estrogen receptor, PR progesterone receptor, HER2 human epithelial growth factor receptor 2